Komori
Share Issuance and Disposal4593HEALIOS K.K.Pharmaceuticals

Notice Regarding the Finalization of the Terms of the Paid Stock Options (30th Series Stock Acquisition Rights)

The previously undecided issuance terms of the paid stock options resolved on 17 June 2026 have been finalized. A total of 54,610 stock acquisition rights will be allocated to the Representative Executive Officer, President and CEO, entitling the holder to acquire 5,461,000 common shares upon exercise.

Worth reading
42Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
5461000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Paid stock options (30th Series of Stock Acquisition Rights)

Who receives how much5,461,000Shares

5,461,000 common shares

Representative Executive Officer, President and CEO of the Company, Kagimoto Tadanao (鍵本忠尚) (1 person, 54,610 rights)

The lower thin line represents the existing number of shares to which these shares will be added.

Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total to be issued: 54,610 rights; unexercised balance: Not disclosed
Categories and Number of Persons Covered
Representative Executive Officer, President and CEO: 1 person, 54,610 rights
Details of issuance or disposal
ItemDetails
Type of issuance or disposalPaid stock options (30th Series of Stock Acquisition Rights)
Number of shares to be issued or disposed of5,461,000 common shares
Intended allotteeRepresentative Executive Officer, President and CEO of the Company, Kagimoto Tadanao (鍵本忠尚) (1 person, 54,610 rights)
Number of Stock Acquisition RightsTotal to be issued: 54,610 rights; unexercised balance: Not disclosed
Categories and Number of Persons CoveredRepresentative Executive Officer, President and CEO: 1 person, 54,610 rights
Items this document does not state (23)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The previously undecided matters concerning the issuance of stock acquisition rights as stock options to Executive Officers have been finalized based on the resolution of the Board of Directors meeting held on 17 June 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Finalization of the Terms of the Paid Stock Options (30th Series Stock Acquisition Rights) | HEALIOS K.K. (4593) timely disclosure | Komori